06 Apr Biomedical Bonding secures 3 MSEK in Vinnova funding for its innovative Bonevolent™ implants
Biomedical Bonding AB has, together with consortium partners KTH Royal Institute of Technology, RISE Research Institutes of Sweden and The Karolinska Institute/Stockholm South General Hospital secured 3 MSEK in funding from Medtech4Health and the SWElife program to fast-track the development of their composite-based universal bone fixators.
The consortium’s proposal was one of fourteen projects that received funding out of 96 applications. With a total budget of 6.74 MSEK, BMB with partners will be able to accelerate the planned activities to ensure product readiness for clinical trials. The project will be headed by Viktor Granskog, CTO at Biomedical Bonding with the emphasis on its innovative composite-based fixation implants for fracture treatments.
“BMB’s quest is to become the first MedTech company to provide implants that adapts to fractures in real-time during surgery opposed to pre-manufactured metal plates. The alliance with KTH, RISE, KI SÖS will speed up our activities to provide Bonevolent products for clinical trials”, says Michael Malkoch, CEO and Founder of BMB.
About SWElife
SWElife – For a competitive life science ecosystem in Sweden.
SWElife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s partners. We support collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health. www.swelife.se
About Medtech4health Medtech4Health strive to increase the number and quality of new innovative products and services within medtech. In collaboration with patients, healthcare, academia and business, we contribute to increasing value for people affected by disease in their everyday lives. Medtech4Health is funded by the Swedish government through the innovation authority Vinnova and by the programme’s partners. www.medtech4health.se
For more information, please contact: Michael Malkoch, CEO and Founder Phone: +46 (0) 8 121 56 755 E-mail: michael.malkoch@biomedicalbonding.com Homepage: www.biomedicalbonding.com
Biomedical Bonding AB is a platform based Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.
SOURCE: Biomedical Bonding, April 4 2022